Press Release: Versatile Platform Chemical Levoglucosenone Provides New Opportunities For Coronavirus Treatments
- Monday, 06 April 2020
YORK, UK – 6 April 2020 – Biotechnology company Circa Group – who produces bio-based solvent CyreneTM in one step from levoglucosenone (LGO) – is offering its LGO manufacturing capability to experts looking for building blocks for coronavirus therapeutics, including ribonolactone.
Circa’s continuous process for producing levoglucosenone from waste cellulose at its FC5 prototype plant in Tasmania, Australia, with partner Norske Skog, is currently producing LGO in tonne quantities.
Tony Duncan, CEO and co-founder of Circa Group, said, “Circa’s expertise to manufacture levoglucosenone has been built up over many years – and now this manufacturing capability can be utilised for production of ribonolactone and other important medicinal chemistry building blocks. We encourage researchers and those investigating potential coronavirus treatments to consider new possibilities that LGO provides.”